Emmenia is built as a closed-loop menstrual pain OS: predict hard days, run phase-timed protocols with inspectable evidence grades, measure what worked for you, and export a clinician-ready summary. This page explains how those claims are grounded — and where we stop short of medical-device or diagnostic language.
What this is (and is not)
- Emmenia is a wellness tracking and education product, not a medical device and not a substitute for clinical care.
- Evidence grades summarise published research in plain language. They are not prescriptions and do not personalise dosing for you.
- Condition pathways (endo red flags, heavy bleeding, PMDD diary) are conversation starters for clinicians — not diagnoses.
Ritual evidence grades (A / B / C)
Each ritual card that maps to a care remedy carries a grade. Grades are assigned from the published literature for menstrual pain or closely related outcomes — not from marketing claims or invented citation IDs.
Grade A — stronger trial support
Multiple randomised trials or meta-analyses for menstrual pain or closely related outcomes.Grade B — some clinical support
Some clinical trials or consistent observational support — useful, with more protocol variation.Grade C — emerging / traditional
Traditional use, small studies, or a strong mechanistic rationale with limited menstrual-specific trials.
Current graded rituals
The table below mirrors what signed-in users see on ritual cards (summary, typical use, cautions, and source notes). Source notes describe study types; we do not fabricate PMIDs.
Heat pad
Grade A — stronger trial supportContinuous low-level heat is comparable to NSAIDs for primary dysmenorrhea in randomised trials and reviews — often easing pain within the first hour when started early.
- Typical use
- 15–20 minutes of warm (not hot) heat over the lower abdomen or back; repeat with skin rests. Many protocols start 60–90 minutes before usual peak pain.
- Cautions
- Avoid high heat or prolonged contact that risks burns
- Do not use over broken skin or with impaired sensation unless a clinician advises
- Seek care for sudden severe pain unlike your usual period pattern
- Source notes
- RCTs and systematic reviews of heat therapy for primary dysmenorrhea
- Clinical guidance favouring non-drug measures alongside analgesia when appropriate
Ginger tea
Grade A — stronger trial supportGinger (often 750–2000 mg/day powdered equivalent across study arms) has meta-analytic support for reducing menstrual pain versus placebo, with several trials finding effects in a similar range to NSAIDs.
- Typical use
- Study protocols commonly use standardised ginger powder capsules across the first 1–3 days of menses; a culinary brew is a lighter, self-managed proxy — log dose and timing for your own n-of-1 read.
- Cautions
- Discuss with a clinician if you take anticoagulants or have gallstones
- Stop and seek advice if you notice reflux, heartburn or allergic symptoms
- Not a substitute for prescribed treatment of secondary dysmenorrhea
- Source notes
- Meta-analyses of ginger for primary dysmenorrhea vs placebo / NSAIDs
- Trial literature on powdered ginger dosing across early menses days
Gentle stretching
Grade B — some clinical supportLow-intensity exercise and stretching programmes show moderate evidence for easing menstrual pain and improving wellbeing versus usual care, though protocols vary widely.
- Typical use
- 5–20 minutes of supported poses or light movement on pain days; consistency across cycles matters more than intensity.
- Cautions
- Skip positions that worsen pain, dizziness or heavy flooding
- Modify or rest if you have acute injury or clinician-advised activity limits
- Source notes
- Reviews of exercise and yoga-style interventions for dysmenorrhea
- Trials of stretching programmes during menstruation
Early night
Grade B — some clinical supportShort or fragmented sleep associates with higher next-day pain sensitivity; protecting luteal-phase sleep is a practical pain-modulation target even when menstrual-specific RCTs are thinner than for heat or ginger.
- Typical use
- Consistent wind-down 30–60 minutes before a fixed bedtime in the luteal window; quiet hours and reduced late caffeine help many people.
- Cautions
- Persistent insomnia, loud snoring or gasping warrants clinical sleep assessment
- Do not use sedating substances without clinician advice
- Source notes
- Pain-science literature on bidirectional sleep–pain links
- Wearable and cohort data linking sleep disruption to cycle symptom burden
Warm bath
Grade B — some clinical supportWarmth via baths shares mechanisms with local heat (muscle relaxation, comfort). Direct menstrual-pain RCTs are fewer than for heat packs, so the grade sits below continuous heat protocols.
- Typical use
- Warm (not scalding) bath 10–20 minutes on cramp days; hydrate afterwards.
- Cautions
- Avoid if dizzy, faint, or advised against hot baths in pregnancy or certain cardiac conditions
- Keep water comfortably warm to avoid burns or overheating
- Source notes
- Heat-therapy evidence base for dysmenorrhea (bath as related modality)
- Clinical self-care guidance for primary period pain
Breathing exercise
Grade C — emerging / traditionalSlow breathing and related autonomic down-regulation can reduce perceived stress and pain intensity for some people; menstrual-specific trial evidence is limited compared with heat or ginger.
- Typical use
- 5–10 minutes of paced breathing (for example longer exhales) at onset of cramps or bedtime.
- Cautions
- Stop if you feel light-headed; return to normal breathing
- Not a crisis intervention for severe pain or distress
- Source notes
- Broader evidence for paced breathing in stress and pain modulation
- Limited condition-specific RCTs for dysmenorrhea
Magnesium
Grade B — some clinical supportMagnesium supplementation has mixed-to-supportive evidence for menstrual pain and PMS symptoms; formulations and doses vary, so personal logging matters.
- Typical use
- Study doses often fall around 200–400 mg elemental magnesium daily in luteal or menstrual windows — confirm form and suitability with a clinician or pharmacist.
- Cautions
- Kidney disease or medication interactions need clinician review first
- High doses can cause diarrhoea; stop and seek advice if severe
- Source notes
- Reviews of magnesium for dysmenorrhea and PMS
- Heterogeneous trial dosing — treat app logs as personal experiments, not prescriptions
Pain relief medication
Grade A — stronger trial supportNSAID analgesics (for example ibuprofen, naproxen) have strong evidence for primary dysmenorrhea when used appropriately; timing before peak pain often improves control.
- Typical use
- Follow the product label or your clinician’s dose; many people do better starting at the first twinge rather than waiting for peak pain.
- Cautions
- Ulcers, kidney disease, asthma sensitivity, pregnancy, or anticoagulant use — check with a clinician
- Do not exceed labelled maximum doses
- Source notes
- Guideline-level evidence for NSAIDs in primary dysmenorrhea
- Comparative trials of NSAIDs vs placebo and vs some non-drug measures
My Evidence (n-of-1)
Population evidence tells you what often works. My Evidence ranks remedies from your care logs — with confidence and sample-size gates so thin data does not look like proof. Optional dose and timing chips help you and a clinician see what you actually tried. Rankings appear on Insights and can export into the clinician report.
Prediction honesty
Pain forecasts show a data-basis band (how much history we have). Verified accuracy appears only after predicted-versus-actual calibration — we do not invent percentage accuracy for marketing.
Clinical adjacency pathways
- Heavy bleeding / endo signals: screening → PBAC-style volume → iron context → clinician pack.
- PMDD pathway: DRSP-style luteal diary, care-plan branch in the luteal window, and a clipboard summary for appointments — educational pattern tracking, not a DSM diagnosis.
- Perimenopause: STRAW+10-informed cycle staging plus vasomotor/mood severity logs in the clinician report — a staging aid, not a menopause diagnosis.
Advisory review
Emmenia does not currently list named clinical advisors on this page. We are assembling an advisory process for evidence grades and pathway copy; until that is live, grades remain product-team syntheses of published literature with the caveats above. We will not invent credentials or affiliations.
Research participation
Privacy settings include an opt-in interest / waitlist preference for a future dysmenorrhea outcomes study. A formal study (with IRB oversight) is not launched yet — flipping the toggle does not enrol you or share data today. When a study opens, separate explicit consent will be required.
Questions
For data rights and controller details, see the Privacy Policy. For product access tiers, see Pricing.